Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1/2 5Phase 1 2Phase NA 1Phase 2/3 1

Status

Recruiting 4Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 7Recurrence 5Neoplasms 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Diseases 1Primary Myelofibrosis 1Neoplasms by Site 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Genital Diseases 1COVID-19 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × selinexor × Clear all
NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
228 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Shandong New Time Pharmaceutical Co., LTD

Phase 3 Recruiting
261 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Chengdu Zenitar Biomedical Technology Co., Ltd

Phase 3 Recruiting
390 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital

Phase 3 Recruiting
50 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03110562 2024-08-21

BOSTON

Karyopharm Therapeutics Inc

Phase 3 Completed
402 enrolled 22 charts 1 FDA
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡